Please assess the completion status of the following clinical trial:

Trial Title: Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Physically active a minimum of 120 minutes a week, as determined by questionnaire~* 18-35 years of age~* Classified as low risk, based on the modified PAR-Q questionnaire, BMI, and non-smoking status~* No history of pulmonary disease and pulmonary function classified as normal, as defined by the following measurements being 80% of predicted values: forced vital capacity (FVC), forced expired volume in one second (FEV1) and FEV1/FVC, according to the American Thoracic Society standards.~Exclusion Criteria:~* Current smoker~* Women who are pregnant or could possibly be pregnant~* BMI \> 25 kg/m2~* A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire~* History of pulmonary disease or \<80% of predicted FCV, FEV1 and/or FEV1/FVC.~* A history of renal or liver disease, due to possible interaction effect with Cetirizine~* Currently taking any prescription or over the counter medications for the treatment of allergies, or taking any of the below listed drugs known to have a moderate or higher interaction effect with Cetirizine:~isocarboxazid tranylcypromine bosutinib clobazam crizotinib daclatasvir eliglustat hyaluronidase lomitapide lurasidone ombitasvir/paritaprevir/ritonavir phenelzine ponatinib ritonavir vemurafenib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Cetirizine/Hypoxia (Type: EXPERIMENTAL): Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
- Placebo/Normoxia (Type: PLACEBO_COMPARATOR): Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
- Placebo/Hypoxia (Type: PLACEBO_COMPARATOR): Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).

Based on this trial design, predict the completion outcome and termination type (if applicable).